Gyre Therapeutics, Inc. Share Price
GYREGyre Therapeutics, Inc. Stock Performance
Open $7.69 | Prev. Close $7.71 | Circuit Range N/A |
Day Range $7.69 - $7.72 | Year Range $6.11 - $13.75 | Volume 829 |
Average Traded $7.71 |
Gyre Therapeutics, Inc. Share Price Chart
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Jan-26 | $7.69 | $7.72 | +0.00% |
16-Jan-26 | $7.69 | $7.72 | +0.13% |
15-Jan-26 | $7.75 | $7.71 | +0.26% |
14-Jan-26 | $7.78 | $7.69 | -1.47% |
13-Jan-26 | $7.88 | $7.80 | +1.30% |
12-Jan-26 | $7.47 | $7.71 | +3.84% |
09-Jan-26 | $7.51 | $7.42 | -2.11% |
FAQs on Gyre Therapeutics, Inc. Share Price
Can I buy Gyre Therapeutics, Inc. shares in India?
What is the share price of Gyre Therapeutics, Inc.?
What is the 5 year returns of Gyre Therapeutics, Inc.?
What are the high & low stock price of Gyre Therapeutics, Inc. today?
What is the 52-week high and low of Gyre Therapeutics, Inc. stock?